1Characteristics analysis of phase Ⅱ clinical trials of new Chinese medicine from 2015 to 2024LEI Xiang, ZHAO Chen, DAI Shun, SUN Hao, XU Ya, OU-YANG Hui-tian, GAO Chun-sheng, CHENG Jin-lian2465-24712Analysis patent applications in therapeutic anti-tumor antibodiesBI Qing, LI Jie2472-24803The first dual endothelin angiotensin receptor antagonist-Filspari(sparsentan)GUAN Li-ye, ZHAO Jian-qun, TIAN Dong-dong, WU Yu-pei, FANG Ling-zhi2481-24854Difficulties and countermeasures for the international acceptance of clinical trial data in ChinaSUN Yi-bu, HAO Zi-ruo, CHEN Yu-wen2486-24895From FDA Complete Response Letters on the pharmaceutical assessment of chemical drugs:critical deficiencies and review considerationsREN Feng, CHENG Si-qi, JIANG Tao, CHEN Ai-ping, TANG Zhi-quan, ZHANG Jing-chen2490-24966A multidisciplinary review of a new drug from the perspective of FDA Complete Response Letters and review reports:a case study of risperidone microspheresCHENG Si-qi, JIANG Tao, CHEN Ai-ping, TANG Zhi-quan, ZHANG Jing-chen, REN Feng2497-25017Discussion on clinical pharmacology of novel anti-obesity drugs:glucagon-like peptide-1 receptor agonistsWANG Jing, LI Li, WEI Chun-min2502-25078Research and application progress of biomarkers for Alzheimer's diseaseZHANG Shi-ye, QI Mei, GU Zhi-rong, GE Bin2508-25169Application of minimal clinically important difference in economic evaluationLI Yan, HU Hong-fei, ZHAO Min, WANG Di, GAO Wei, LI Hong-chao2517-252510Construction of breaking the blind risk assessment content for investigator test site in double-blind clinical trials of traditional Chinese medicine and suggestions for maintenance of blinding in clinical trialsYANG Fang-fang, PAN Ding-ju2526-253011Construction and exploration of information management system for biological samples in phase Ⅰ clinical trialsSHEN Jie, LI Sha, ZHAO Juan, GONG Li, YANG Hui-yao, Li Yong-sheng, ZHONG Ming, LIAO Bin2531-254012Qualitative and quantitative study of constituents in Chuanshentong injection based on UHPLC-Q-Exactive Plus Orbitrap HRMS and HPLC-UVZHU Xing-yu, ZHANG Xiong-li, LI Hua-liu, CHI Ming-yan, HUANG Yong, ZHENG Lin, XIAO Hai-tao, HE Feng2541-255113Mechanism of compound danshen dripping pills in ameliorating atherosclerosis in ApoE-/-mice with hyperlipidemiaZHANG Shuang-li, GE Shi-hui, GE Zi-meng, ZHANG Bei-bei, MIAO Ming-san, WANG Jun, MIAO Jin-xin2552-256414Effect of azvudine on the pharmacokinetics of ibuprofen in healthy volunteersGONG Meng, LIU Xiao-jian, JU Hao-shuang, WAN Yuan-hao, DING Xue, ZHANG Sheng-bang, JIA Ya-qiang, ZHANG Wei, XU Ping2565-256915Clinical characteristics of four cases of myositis,myocarditis and myasthenia gravis overlap syndrome induced by immune checkpoint inhibitorsLI Xiao, ZHANG Yan-hua2570-2576 